Pulmonology

A six-month study shows the common OSA therapy could have long-term benefit for reducing eventual cardiovascular risk.

Treatment drug results in a significant reduction in severe exacerbations for patients with eosinophil ≥150 cells/µL.

An assessment of FF/UMEC/VI in a single inhaler show its benefit in respiratory function among COPD patients at 24 weeks.

A 52-week assessment shows patients of varying interleukin serum levels equally benefitted from the TSLP inhibitor.

New trial testing vitamin D supplementation in pediatric asthma patients was stopped early because of ineffective data.

New ATS findings show the IL-5 inhibitor has sustained and oftentimes improved benefit in patients from 6 months to 12.

Dr. Ian Pavord discusses new meta-analyses of dupilumab planned for ATS 2020 on the DocTalk podcast.

When compared to placebo, benralizumab results in a significantly improved asthma exacerbation rates.

New research show younger age is associated with a non-response to biologic agents.

While initial double therapy has proven effective in treating pulmonary arterial hypertension, adding selexipag to the treatment regimen of macitentan and tadalafil could be beneficial in this patient population.

Patients with the splice variant were significantly less likely to have raised blood eosinophil counts.

Electronic nicotine device use could lead to a number of respiratory outcomes such as wheezing and dry coughs.

A new study shows consistent confidence and anxiety of self-care with the injectable biologic in patients with asthma.

In a pair of Canadian cohorts, investigators discover asthmatic children are older on the epigenetic clock.

Greater BMI scores are linked to longer ventilator needs and higher risk of acute respiratory distress syndrome.

An assessment of a combined pharmacologic and cognitive behavioral therapy program shows patients improve FEV1, FVC, and other metrics.

Between 2006-2016, the hospital mortality rates for patients with ILD did not change.

New cohort data comparing the lone regulated IPF therapies show one is associated with reduced mortality—while the other has a better continuation of care.

A story of how a clinician, mentor, father, and husband is handling the COVID-19 pandemic on the frontlines and social media.

Investigators find individuals with asthma who slept less than 5 hours per night had increased asthma attacks and overnight hospitalizations.

Despite being advised in clinical guidelines, fewer than 2% of COPD patients initiate pulmonary rehabilitation within 90 days of hospitalization.

An analysis of the CITU study is shedding light on the impact of e-cigarette use on arterial stiffness and vascular health.

Prenatal exposure to air pollutants has a lasting effect on growth after birth.

California is home of the cities with the most unhealthy pollution levels, according to the newest annual report from the ALA.

New findings comparing 3 decades of newly approved indications show the proportion of new approvals being supported by just 1 pivotal trial has quadrupled.

Investigators assessing the link from CO to pneumonia risk—and the benefit of biomass-fueled cookstoves in reducing them—find it is not very distinct.

Patients too frequently self-assess their pneumonia risk, therefore reducing the efficacy of preventive measures.

Can positive ELISA test results better interpret for how much longer social distancing must continue?

Dr. Rapoport of Mount Sinai discusses the clinical ingenuity fostered by the pandemic response, and what US healthcare must improve on in the near future.

Pathogenic mechanism between respiratory exposures and the development of AAV could be established in future research.